Sector News

Bayer HealthCare's faltering even before Monsanto enters the fold

March 1, 2018
Life sciences

Industry watchers were worried about Bayer neglecting its healthcare division after the company chased down a megamerger with agrochemical giant Monsanto. But that deal hasn’t even closed yet, and healthcare sales are already showing cause for concern.

Wednesday, the German drugmaker unveiled fourth-quarter pharma sales of €4.21 billion, 4% below consensus estimates. Only one of Bayer’s five key growth products—a group consisting of eye drug Eylea, anticoagulant Xarelto, pulmonary arterial hypertension treatment Adempas and cancer therapies Stivarga and Xofigo—beat analyst estimates for the quarter, and that was Eylea, which came out 5.2% ahead.

Xofigo missed its €106 million target with just €90 million in sales, while Stivarga managed just €77 million. Another key miss came from hemophilia treatment Kogenate, which checked in 11% below projections.

Consumer health sales for the quarter also took a hit, thanks to China’s move to switch two skincare brands from OTC to prescription. The move precipitated a €70 million sales decline, Bernstein analyst Jeremy Redenius wrote in a note to clients.

Bayer’s 2018 outlook didn’t inspire a whole lot of confidence, either. As Redenius put it, it “looks to be soft vs. consensus,” with the company expecting €16.5 billion in pharma sales—more than $1 billion less than the €17.6 billion analysts expected. On the consumer side, Bayer expects €5.5 billion, short of Wall Street’s €6 billion guess. And as far as earnings go, the Leverkeusen-based company expects its bottom-line tally for both units to decline by a single-digit percentages before special items.

While Bayer’s consumer health segment has been struggling since 2014’s $14.2 billion fold-in of Merck’s OTC products, the pharma woes are newer. The company has touted big things ahead for the Eylea-Xarelto-Adempas-Stivarga-Xofigo group, even raising its guidance for the drugs in late 2016 to ease Monsanto-related fears.

But the third quarter didn’t exactly go as planned either—Redenius labeled those results “messy.” And with the Monsanto deal sapping funds that could have been used to develop Bayer’s pharma pipeline, that’s not a good sign.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.